Latest: ceftriaxone is becoming “increasingly resistant” to infections.

Researchers from Kerala had noticed a rise in ceftriaxone resistance last year. Ceftriaxone is a third-generation cephalosporin that works well against several gram-negative bacteria, which are more challenging to treat.

According to a top NCDC official connected to the government survey, “this is exactly the point of this survey that analysed antibiotic usage patterns for hospitalised patients across specialities,” ThePrint was informed. “In order to rationalize the use of antibiotics, we wanted to know which ones are being consumed more frequently.”

Due to the widespread prescription of ceftriaxone, one well-known brand of the medication, Monocef, manufactured by Mumbai-based Aristo Pharmaceuticals, has been among the top-selling medications in the nation for the past several months, according to data from market research firm IQVIA.Monocef, a popular brand of the drug, has been among top-selling medicines these last few months. Ceftriaxone is ‘watch’ antibiotic, with high potential for antimicrobial resistance.

Patients with bacterial meningitis, respiratory tract infections, urinary tract infections, soft tissue infections of the bones and joints, and gonorrhea are typically recommended ceftriaxone. In addition to being safe and effective, it also has fewer adverse effects (with the exception of diarrhea in rare circumstances) and is not a worry for most people who use it.

The Keralan researchers who had discovered ceftriaxone resistance the previous year stated that “this demands immediate attention.” The researchers recommended that “resistance prevention mechanisms be strictly enforced” in light of their findings.

Due to the widespread prescription of ceftriaxone, one well-known brand of the medication, Monocef, manufactured by Mumbai-based Aristo Pharmaceuticals, has been among the top-selling medications in the nation for the past several months, according to data from market research firm IQVIA.

Monocef was able to take a sizable portion of the antibiotic market in India, which is among the biggest in the world. As of the time of publication, ThePrint had not heard back from Aristo Pharma. If and when a response is obtained, this report will be updated.